Enzolytics is trading at 7.0E-4 as of the 16th of March 2025, a 12.5 percent decrease since the beginning of the trading day. The stock's open price was 8.0E-4. Enzolytics has more than 69 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. The company has 2.44 B outstanding shares. More on Enzolytics
Enzolytics [ENZC] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Small-Cap' category with a current market capitalization of 125.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Enzolytics's market, we take the total number of its shares issued and multiply it by Enzolytics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Enzolytics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 2.44 B outstanding shares.
Enzolytics currently holds about 5.76 K in cash with 4.89 M of positive cash flow from operations.
Check Enzolytics Probability Of Bankruptcy
Our tools can tell you how much better you can do entering a position in Enzolytics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Portfolio Volatility Now
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Other Information on Investing in Enzolytics Pink Sheet
Enzolytics financial ratios help investors to determine whether Enzolytics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Enzolytics with respect to the benefits of owning Enzolytics security.